Research Topics
| D E TsaiSummaryAffiliation: University of Pennsylvania Country: USA Publications
| Collaborators
|
Detail Information
Publications
Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemiaDonald E Tsai
Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
Leuk Lymphoma 45:591-5. 2004..The patient had a complete response to the treatment, including disappearance of any detectable IgM paraprotein. This case report demonstrates the potential for radioimmunotherapy in CD20 positive B-cell malignancies...
EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trialD E Tsai
Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA, USA
Am J Transplant 8:1016-24. 2008..We conclude that EBV PCR is a useful test for managing PTLD patients. While plasma EBNA PCR is the best single assay for diagnosing and monitoring PTLD, the complete PCR panel is superior for ruling out its presence...- A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemiaDonald E Tsai
Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Clin Cancer Res 14:5619-25. 2008..We therefore conducted a phase I dose escalation study to assess the maximum tolerated dose, toxicities, and activity of bexarotene in patients with non-M3 acute myeloid leukemia (AML)... - Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibodyDonald E Tsai
Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, 19104, USA
Clin Lymphoma 4:56-9. 2003..This case report demonstrates the potential for repeated treatments with radioimmunotherapy agents in patients with chemotherapy-refractory non-Hodgkin's lymphoma... - Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexaroteneDonald E Tsai
Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
Am J Transplant 5:2070-3. 2005..The patient was successfully treated with bexarotene, a novel synthetic retinoid analog, achieving a complete clinical response. Bexarotene may be a promising treatment for T-cell PTLD... - Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexaroteneDonald E Tsai
Hematology Oncology Division, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
Cancer Biol Ther 6:18-21. 2007..These data suggest that bexarotene has clinical activity in non-M3 AML and may be able to induce myeloid differentiation in vivo... - Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patientsDonald E Tsai
Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
Am J Transplant 2:946-54. 2002..We conclude that peripheral blood EBV PCR may have a role in the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients... - Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorderDonald E Tsai
Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
Clin Transplant 19:644-52. 2005..68 wk, p = 0.003). Persistence of MG after complete response of the PTLD did not predict relapse. There is a high incidence of MG and gammaglobulin abnormalities in patients with PTLD... - Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapyD E Tsai
Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
Clin Lymphoma 1:62-6. 2000..Both patients achieved a rapid response to the radiolabeled antibody with minimal toxicity. Monoclonal antibody therapy may be an effective and tolerable treatment for progressive NHL after PSCT... - Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patientsD E Tsai
Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
Transplantation 71:1076-88. 2001..With the increased use of organ transplantation and intensive immunosuppression, this disease is becoming more common. We explore reduction in immunosuppression as an initial therapy for PTLD... - Hypertriglyceridemia presenting as "pink blood" and elevated hemoglobin levelDonald E Tsai
Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
Am J Hematol 83:253. 2008 - Treatment of PTLD with rituximab or chemotherapyR L Elstrom
Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, USA
Am J Transplant 6:569-76. 2006..PTLD patients requiring therapy beyond RI should be considered for rituximab, especially with EBV-positive disease. Chemotherapy should be reserved for patients who fail rituximab, have EBV-negative tumors or need a rapid response... - Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphomaC Andreadis
Bone Marrow and Stem Cell Transplantation Program and Lymphoma Program, The Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, Philadelphia, 19104, USA
Bone Marrow Transplant 36:955-61. 2005..ASCT is thus a safe therapeutic approach in FL, resulting in long-term EFS and OS for some patients, even with transformed disease... 
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myelomaR L Olin
Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Bone Marrow Transplant 43:417-22. 2009..We conclude that in well-selected patients, salvage auto-SCT is safe and effective for relapsed myeloma...- Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen casesHimisha Patel
Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
Leuk Lymphoma 48:885-91. 2007..Although detection and treatment of PTLD in liver transplant recipients remains problematic and upfront mortality is still high, long-term survival is possible. Further studies are necessary to better define treatment strategies... - Stem cell transplantation for metastatic breast cancer: analysis of tumor contaminationE A Stadtmauer
Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
Med Oncol 16:279-88. 1999.... - Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantationA W Loren
Bone Marrow and Stem Cell Transplant Programs, University of Pennsylvania Cancer Center, Philadelphia, PA, USA
Bone Marrow Transplant 35:921-6. 2005..05). The combination of Cs/MMF is inadequate GVHD prophylaxis for UD-NST. The use of Cs, MTX, and alemtuzumab eliminated severe acute GVHD; its impact on response merits further study... - Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive diseaseA D Cohen
Hematologic Malignancies Program and the Bone Marrow and Stem Cell Transplantation Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
Bone Marrow Transplant 30:23-8. 2002..The other seven patients did not meet diagnostic criteria for VOD. We conclude that GO can be safe and effective in patients who relapse following HSCT, but that caution is warranted in patients with multiple risk factors for VOD... - The management of posttransplant lymphoproliferative disorderNoelle V Frey
University of Pennsylvania Cancer Center, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA
Med Oncol 24:125-36. 2007..Further investigations are needed to better define the role of more novel and less widely available therapies such as the adoptive transfer of EBV-specific T cells and optimization of antiviral therapies... - Successful treatment of relapsed lymphomatoid granulomatosis with bexaroteneSigrid E Berg
Abramson Cancer Center, Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, PA 19104, USA
Cancer Biol Ther 7:1544-6. 2008..We present a case of successful treatment of relapsed lymphomatoid granulomatosis with bexarotene, a novel retinoid agent... - Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★)R Reshef
Abramson Cancer Center Department of Biostatistics and Epidemiology Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Am J Transplant 11:336-47. 2011..Patients with none or one of these factors had a 3-year overall survival of 100% and 79%, respectively. These findings support the use of RI alone in low-risk PTLD and suggest factors that predict response and survival... - A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemiaAlexander E Perl
Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Clin Cancer Res 15:6732-9. 2009..We sought to determine the safety and describe the toxicity of this approach by adding the mTOR inhibitor, sirolimus (rapamycin), to intensive AML induction chemotherapy... - Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejectionVivek N Ahya
Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
J Heart Lung Transplant 26:839-44. 2007..We investigated the hypothesis that detection of latent Epstein-Barr virus (EBV) in peripheral blood may be a functional marker for the net effects of administered immunosuppression... - Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphomaBradley G Somer
University of Pennsylvania Cancer Center, Philadelphia, USA
Arthritis Rheum 49:394-8. 2003 - Management of patients with post-transplant lymphoproliferative disorder: the role of rituximabJakub Svoboda
University of Pennsylvania Cancer Center, Bone Marrow and Stem Cell Transplant Program, Philadelphia, 19104, USA
Transpl Int 19:259-69. 2006..This paper reviews the current data on rituximab and its promising role in the management of PTLD... - Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell supportDan T Vogl
Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Am J Hematol 82:1071-5. 2007..Future trials comparing induction therapies should examine progression-free and overall survival after transplant to confirm this benefit... - Use of serum protein electrophoresis to monitor patients with post-transplant lymphoproliferative disorderNicole A Aqui
Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Am J Transplant 3:1308-11. 2003..The amount of M protein paralleled the disease course, decreasing as the clinical symptoms improved. This case illustrates the utility of using SPEP to monitor patients with PTLD... - Post-transplant lymphoproliferative disorder: a reviewA W Loren
Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
Bone Marrow Transplant 31:145-55. 2003.... - Treatment advances in posttransplant lymphoproliferative diseaseCourtney D DiNardo
Department of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania, Pennsylvania, Philadelphia 19104, USA
Curr Opin Hematol 17:368-74. 2010..Several innovative therapeutic approaches are currently under development to add to our arsenal of treatment strategies in this devastating disease... - Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexaroteneCourtney D DiNardo
Department of Internal Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
Med Oncol 25:299-302. 2008..This case emphasizes the importance of monitoring for differentiation syndrome among patients receiving retinoid therapies and demonstrates the ability of bexarotene to stimulate differentiation of leukemic blasts... - A peptide-based inhibitor for prevention of B cell hyperproliferation induced by Epstein-Barr virusJason S Knight
Department of Microbiology, University of Pennsylvania Medical School, 201E Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
Virology 354:207-14. 2006..Importantly, the peptide inhibited lymphoblastoid outgrowth from the blood of an EBV-positive transplant patient in vitro... - Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrowRebecca L Elstrom
Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, 17104, USA
Clin Lymphoma 5:62-4. 2004..However, iliac crest bone marrow examination showed marked myeloid hyperplasia without evidence of lymphoma involvement. We discuss the implications for interpretation of FDG-PET imaging of bone marrow in lymphomas... - Primary lymphomas of the cervix and uterus: the University of Pennsylvania's experience and a review of the literatureNoelle V Frey
Abramson Cancer Center of the Hospital of the University of Pennsylvania, 3400 Spruce, Philadelphia, PA 19104, USA
Leuk Lymphoma 47:1894-901. 2006..In general, patients with limited stage disease should be treated with localized and systemic therapy to optimize chances of cure... - Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapyMichael C Milone
Department of Pathology and Laboratory Medicine, Hematologic Malignancies Program, University of Pennsylvania, Philadelphia, USA
Blood 105:994-6. 2005..These data suggest that the pre-emptive use of B-cell-directed therapy may reduce the morbidity and mortality of primary EBV infection in XLP-affected individuals... - Detection of Epstein-Barr virus in T-cell prolymphocytic leukemia cells in vitroKe Lan
Department of Microbiology and the Tumor Virology Program of Abramson Comprehensive Cancer Center, University of Pennsylvania Medical School, 201E Johnson Pavilion, Philadelphia, PA 19104, U S
J Clin Virol 43:260-5. 2008.... - Regression of pulmonary MALT lymphoma after treatment with rituximabElise A Chong
Hematology-Oncology Division, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
Leuk Lymphoma 46:1383-6. 2005..This case report demonstrates the potential efficacy of rituximab as a single therapeutic agent in patients with pulmonary MALT lymphoma... - Removal of gadolinium by peritoneal dialysisM Murashima
Renal Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
Clin Nephrol 69:368-72. 2008.... - Post-transplant lymphoproliferative disorderAlison W Loren
Division of Hematology/Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Clin Chest Med 26:631-45, vii. 2005..An increasing variety of highly effective therapies, including immune modulation via reduction in immunosuppression, monoclonal antibodies, and cellular therapy, have dramatically improved the cure rates of this once devastating disease... - Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiationDan T Vogl
Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA
Leuk Lymphoma 46:1313-20. 2005..Physicians should be aware of the potential for developing a gemcitabine-induced radiation recall reaction resulting in hemodynamically significant pericardial effusion... - Methotrexate clearance by high-flux hemodialysis and peritoneal dialysis: a case reportMiho Murashima
Department of Medicine, Renal Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
Am J Kidney Dis 53:871-4. 2009..124 +/- 0.037 mL/min/kg (0.00207 +/- 0.00062 mL/s/kg). Despite lower clearance by means of peritoneal dialysis compared with hemodialysis, the patient did not develop clinical evidence of methotrexate toxicity... - Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?Robert M Sharkey
Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109, USA
J Nucl Med 44:2000-18. 2003..Of particular interest was to evaluate whether pretherapy targeting and tumor dosimetry could predict therapeutic responses... - Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphomaJohn P Leonard
Weill Medical College of Cornell University, New York, New York, USA
Clin Cancer Res 13:6168-74. 2007..This Phase I trial was designed to investigate the safety, tolerability, and preliminary antitumor activity of PF-3512676 in combination with rituximab... - Posttransplant lymphoproliferative disorderMatthew J Everly
University of Cincinnati, Cincinnati, OH 45267, USA
Ann Pharmacother 41:1850-8. 2007..To define and discuss the pathogenesis, clinical presentation, diagnosis, risk factors, and current preventive and treatment strategies of posttransplant lymphoproliferative disorder (PTLD)...